Bajaj Healthcare Ltd. is a pharmaceutical company, which is engages in the development, manufacturing, and supply of amino acids, nutritional supplements, and active pharmaceutical ingredients. The company is headquartered in Thane, Maharashtra and currently employs 1,063 full-time employees. The company went IPO on 2016-05-10. The firm is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. The company is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. The company also offers Inositol Nicotinate and Magnesium L-Threonate.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.